Zanzalintinib for Advanced Thyroid Cancer Before Surgery
This study is looking at how well zanzalintinib works and how safe it is when given before surgery for advanced thyroid cancer. This includes differentiated thyroid cancer, medullary thyroid cancer (that does not have a specific genetic change called RET mutation), or poorly differentiated thyroid cancer. You may be able to join if your cancer has spread to nearby tissues or lymph nodes, or if you have advanced recurrent or bulky cancer in your lymph nodes. The study will measure success by seeing how many participants have their tumors shrink or disappear (called objective response rate). The study plans to enroll 45 participants. The current status of this study is unclear.
- Study design
- This study plans to enroll 45 participants. It is looking at the effectiveness and safety of zanzalintinib given before surgery.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Safety and side effects will be measured from the start of treatment until the completion of neoadjuvant therapy, which is an average of 6 months.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before Surgery
At a glance
Conditions
Where it's being run
4 sites across 4 statesStudy leadership
- Mark Zafereo, MD · PRINCIPAL_INVESTIGATOR · M.D. Anderson Cancer Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Safety and adverse eventsFrom baseline until completion of neoadjuvant therapy; an average of 6 months
Defined as the proportion of patients who have a MR, PR, or CR per modified RECIST 1.1. CR and PR are defined using the same criteria as in RECIST 1.1. MR is defined as a 15% or greater decrease in the sum of the longest diameters of target lesions but not a PR. The MR+PR+CR response rate will be determined by dividing the number of patients with modified RECIST-based MR, PR, or CR divided by the number of evaluable patients